This article was originally published May 12.
LifeCodexx of Germany and its parent company GATC Biotech are developing a next-gen sequencing-based diagnostic test for the early detection of preeclampsia, the firms said last week.
The test will detect cell-free fetal DNA as an early marker of the hypertension condition, which affects about two to five percent of pregnancies in Germany and is the leading cause of death in pregnant women.
Get the full story with
GenomeWeb Premium
Only $95 for the
first 90 days*
A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.
Try GenomeWeb Premium now.
Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
